Selpercatinib Proves Mettle in Thyroid, NSCLC
Physician's Weekly,
LIBRETTO-011 data back accelerated OK for RET…
LIBRETTO-011 data back accelerated OK for RET…
(Nogas1974, Wikimedia Commons) 7 January 2018. Drug maker Eli Lilly and Company is acquiring a developer of cancer therapies…
Learn how this newly approved cancer drug scored high patient response rates by inhibiting a rare chromosomal abnormality that…
(Christoph Bock, Wikimedia Commons) 27 Nov. 2018. The Food and Drug Administration yesterday approved a treatment for solid…
ESMO press statement
Larotrectinib, a first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of…
Initial results from a series of three small clinical trials of a targeted cancer therapy called larotrectinib suggest that it…
Robert C. Doebele, MD, PhD In 2013, the labs of University of Colorado Cancer Center investigator Robert C. Doebele, MD, PhD…
(National Cancer Institute) 22 February 2018. Results from 3 clinical trials show most cancer patients given an experimental…
Robert C. Doebele, MD…